Table 2.

Efficacy of As2O3 Treatment in APL

Group Treatment Case Numbers CR (%) Days to CR (Medium)
Newly diagnosed patients As2O3 As2O3 + Chemo  7 4  6 (85.7%) 2 (50.0%)  30 to 36 (35) 36 to 36 (36)  
Relapsed patients As2O3 As2O3 + Chemo  31 11  26 (83.9%) 9 (81.8%)  17 to 76 (30) 25 to 63 (35)  
 As2O3 + ATRA  5 5 (100.0%)  19 to 46 (39) 
Group Treatment Case Numbers CR (%) Days to CR (Medium)
Newly diagnosed patients As2O3 As2O3 + Chemo  7 4  6 (85.7%) 2 (50.0%)  30 to 36 (35) 36 to 36 (36)  
Relapsed patients As2O3 As2O3 + Chemo  31 11  26 (83.9%) 9 (81.8%)  17 to 76 (30) 25 to 63 (35)  
 As2O3 + ATRA  5 5 (100.0%)  19 to 46 (39) 
View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal